RTP Mobile Logo

Saturday, November 17, 2018, Santa Monica, California, 8:00 AM – 4:00 PM

Year in Review — A Multitumor Regional Symposia Series Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

 

Event Details

Date:
Saturday, November 17, 2018

Program Time:
8:00 AM – 4:00 PM
Breakfast and lunch buffet to be provided

Location:
Fairmont Miramar Hotel & Bungalows
101 Wilshire Blvd
Santa Monica, CA 90401
Hotel Phone: (310) 576-7777

Meeting Room:
Starlight Ballroom (Lobby Level)

 
There is no registration fee for this event. Preregistration is advised as seating is limited.


Faculty:
Acute Leukemias

Harry P Erba, MD, PhD
Instructor, Department of Medicine
Duke Cancer Institute
Duke University School of Medicine
Durham, North Carolina

Wendy Stock, MD
Anjuli Seth Nayak Professor of Leukemia Research
Director, Leukemia Program
University of Chicago Medicine
Chicago, Illinois

Breast Cancer

Sara A Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology/Oncology
University of California, Los Angeles
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, California
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
Santa Monica, California

Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Celebrating Women Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas

Gastrointestinal Cancers

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic, Arizona
Scottsdale, Arizona

Johanna C Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Nashville, Tennessee

Wells A Messersmith, MD
Professor and Director
GI Medical Oncology Program
Co-Leader, Developmental Therapeutics Program
University of Colorado Cancer Center
Aurora, Colorado

Genitourinary Cancers

Peter H O’Donnell, MD
Associate Professor, Department of Medicine
Section of Hematology/Oncology
Genitourinary Oncology Program
The University of Chicago
Chicago, Illinois

Daniel P Petrylak, MD
Professor of Medicine
Director, Prostate and GU Medical Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut


Lung Cancer

Edward B Garon, MD, MS
Associate Professor
Director, Thoracic Oncology Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Roy S Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut

Lymphoma and Chronic Lymphocytic Leukemia

Craig Moskowitz, MD
Physician in Chief, Cancer Service Line
Sylvester Comprehensive Cancer Center
University of Miami
Miami, Florida

Jeff Sharman, MD
Medical Director of Hematology Research
The US Oncology Network
Director of Research
Willamette Valley Cancer Institute
Eugene, Oregon

Sonali M Smith, MD
Associate Professor
Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Ovarian Cancer

Gottfried E Konecny, MD
Professor-in-Residence
Division of Hematology-Oncology
Department of Medicine, David Geffen School of Medicine
UCLA Medical Center
Santa Monica, California

Kathleen Moore, MD
Jim and Christy Everest Endowed Chair in Cancer Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

 

Agenda

Each module will include a moderated slide presentation reviewing key publications, presentations and ongoing trials in addition to a clinical decision-making track facilitated through the use of networked tablet technology. The event will take place from 8:00 AM to 4:00 PM (breakfast and lunch buffets to be provided).

MODULE 1: Lymphoma and Chronic Lymphocytic Leukemia (CLL) 8:05 AM – 9:25 AM

  • MRD assessment in CLL: Available platforms, clinical significance and current protocol and nonresearch applications
  • Selection and sequencing of therapy for patients with newly diagnosed and relapsed CLL
  • Practical integration of venetoclax into current clinical algorithms for relapsed disease
  • Available data and current and potential role of acalabrutinib in the management of CLL
  • Biologic rationale for, early activity with and ongoing evaluation of novel combination approaches for untreated or relapsed/refractory (R/R) CLL (eg, ibrutinib/FCR, ibrutinib/venetoclax, ibrutinib/obinutuzumab)
  • Clinical and research implications of the Phase III RELEVANCE trial results evaluating the “R-squared” regimen of lenalidomide/rituximab in newly diagnosed follicular lymphoma (FL)
  • Emerging data from the Phase III AUGMENT trial of R-squared in R/R FL
  • Current clinical role of obinutuzumab-based induction and maintenance therapy for previously untreated FL
  • Mechanism of action, available efficacy and safety data and FDA approval of copanlisib for R/R FL
  • Clinical implications of the recent FDA approval of brentuximab vedotin (BV) with doxorubicin/vinblastine/dacarbazine (AVD) as first-line therapy for advanced classical Hodgkin lymphoma (HL)
  • Anti-PD-1/PD-L1 antibodies for newly diagnosed or R/R HL: Long-term outcomes and ongoing investigation in combination with other agents (eg, BV, anti-CTLA-4 antibodies)
  • Available data and ongoing evaluation of novel agents (eg, bortezomib, lenalidomide, ibrutinib, acalabrutinib) as a component of induction therapy for untreated mantle cell lymphoma (MCL)
  • Mechanism of action, tolerability and FDA-endorsed indication for the second-generation Bruton tyrosine kinase inhibitor acalabrutinib in R/R MCL
  • Early data and potential nonresearch role of venetoclax — alone or in combination with ibrutinib — for treatment-refractory MCL
  • Available data with approved and investigational anti-CD19 CAR T-cell platforms for patients with large B-cell lymphomas
  • Patient identification and appropriate referral for consideration of axicabtagene ciloleucel and tisagenlecleucel therapy
  • Biologic rationale for, early results with and ongoing investigation of other novel agents and immunotherapeutic strategies for diffuse large B-cell lymphomas (eg, lenalidomide, polatuzumab vedotin, anti-PD-1/PD-L1 antibodies)

MODULE 2: Breast Cancer (BC) 9:25 AM – 10:15 AM

  • TAILORx intermediate-risk cohort results and implications for the use of the 21-gene signature assay to facilitate decision-making regarding adjuvant systemic therapy
  • Available research data guiding the use of approved CDK4/6 inhibitors for pre-, peri- and postmenopausal patients diagnosed with ER-positive metastatic BC (mBC)
  • Recently published data sets supporting the ongoing investigation of other novel agents and strategies for patients with ER-positive disease
  • FDA approval and patient selection for pertuzumab as a component of adjuvant therapy for early HER2-positive BC
  • Optimal integration of postadjuvant neratinib into current clinical algorithms; prophylaxis and expectant management of associated side effects
  • Optimal management of HER2-positive metastatic disease; novel HER2-directed therapies
  • Indications for BRCA analysis in BC and optimal testing platforms
  • Phase III data sets documenting the efficacy of PARP inhibitors in patients with germline BRCA-mutated, HER2-negative mBC; integration of olaparib into current algorithms
  • Available data and ongoing evaluation of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other therapeutic agents
  • Emerging results from the Phase III IMpassion130 trial evaluating atezolizumab in combination with nanoparticle albumin-bound (nab) paclitaxel as first-line therapy for metastatic triple-negative BC

MODULE 3: Gastrointestinal (GI) Cancers 10:30 AM – 11:40 AM

  • Clinical decision-making for patients with newly diagnosed metastatic colorectal cancer (CRC): Importance of biomarker profile, primary tumor sidedness, prior therapy and other factors
  • Rational incorporation of anti-EGFR therapy, regorafenib and TAS-102 into current treatment algorithms; patient selection, side-effect management and optimal dosing/sequencing
  • FDA approval of and patient selection for nivolumab in combination with ipilimumab for mismatch repair-deficient/microsatellite instability-high CRC
  • Identification of and treatment for patients with other potentially targetable genetic abnormalities (eg, BRAF, HER2)
  • Integration of ramucirumab into clinical algorithms for metastatic HER2-negative and HER2-positive gastric/gastroesophageal junction (GEJ) cancer
  • Available trial data with anti-PD-1/PD-L1 antibodies in patients with advanced gastric/GEJ cancer; optimal integration of pembrolizumab into current clinical algorithms
  • Design, entry criteria and key efficacy and safety data from the Phase III TAGS study of TAS-102 for previously treated metastatic gastric cancer
  • Available Phase III data comparing lenvatinib to sorafenib for advanced hepatocellular carcinoma (HCC); recent FDA approval of lenvatinib for first-line therapy
  • Sequence and selection of approved options for patients with progressive HCC who have previously received sorafenib
  • Available research data and ongoing evaluation of anti-PD-1/PD-L1 antibodies for HCC
  • Major efficacy and tolerability findings from the CELESTIAL trial; potential clinical role of cabozantinib in the management of HCC
  • Key efficacy outcomes from the REACH-2 study; improvement in overall and progression-free survival with ramucirumab for patients with progressive HCC and elevated alpha-fetoprotein levels
  • Efficacy and safety results from the Phase III PRODIGE 24/CCTG PA.6 trial comparing adjuvant mFOLFIRINOX to gemcitabine for patients with resected pancreatic cancer
  • Current nonresearch role, if any, of FOLFIRINOX or nab paclitaxel/gemcitabine in the neoadjuvant and adjuvant settings
  • Selection and sequencing of therapy for patients with metastatic pancreatic cancer; optimal integration of nanoliposomal irinotecan into clinical practice
  • Incidence of BRCA1/2 mutations in patients with pancreatic cancer; available data and ongoing evaluation of PARP inhibitors for metastatic pancreatic cancer
  • Ongoing investigation of other novel agents and strategies in metastatic pancreatic cancer (eg, PEGPH20, napabucasin, ibrutinib)
  • Current clinical algorithms for the management of GI neuroendocrine tumors (NET)
  • Optimal employment of long-acting somatostatin analogues for patients with GI NET
  • Recent FDA approval and current clinical role of lutetium 177Lu Dotatate for gastroenteropancreatic carcinoid NET

MODULE 4: Ovarian Cancer (OC) 11:40 AM – 12:20 PM

  • Identification of “BRCA-like” and other genomic signatures (eg, HRD) that may predict benefit from PARP inhibition
  • Effect of BRCA mutation status on the activity of PARP inhibitors in OC; proposed mechanisms of anticancer activity in patients without an identified BRCA mutation
  • Current clinical role of bevacizumab as a component of up-front and/or maintenance therapy for newly diagnosed OC
  • Emerging data from the Phase III SOLO-1 trial evaluating maintenance therapy with olaparib for patients with BRCA-mutated OC after first-line platinum-based chemotherapy
  • FDA indications and patient selection for niraparib, olaparib or rucaparib for platinum-sensitive recurrent OC; patient- and disease-specific factors that influence the prioritization of one agent versus another
  • Available data documenting the correlation between low baseline body weight or platelet counts and adverse events with niraparib; implications for initial dosing
  • Design, recently presented results and clinical implications of the Phase II QUADRA study of niraparib for patients with relapsed OC, regardless of mutation status, who have received 3 or more prior chemotherapy regimens
  • Early efficacy and tolerability data with PARP inhibitors in combination with chemotherapy and/or anti-angiogenic agents; late-stage clinical trials
  • Biologic rationale and eligibility criteria for ongoing trials of PARP inhibitors combined with immune checkpoint inhibitors
  • Mechanism of action, safety and efficacy findings and ongoing trials of mirvetuximab soravtansine for OC
  • Available data and ongoing evaluation of anti-PD-1/PD-L1 antibodies alone or in combination with other therapies for OC
  • Other targeted agents under investigation in OC

MODULE 5: Lung Cancer 1:10 PM – 2:15 PM

  • Optimal integration of osimertinib into current treatment algorithms; effect of EGFR variant, if any, on the selection of first-line therapy
  • Available clinical trial data guiding the selection of first and subsequent lines of therapy for patients with newly diagnosed ALK-positive non-small cell lung cancer (NSCLC)
  • Current and emerging treatment options for patients with ROS1 translocations or BRAF V600E tumor mutations
  • Protocol and nonresearch options for patients with other oncogenic drivers (eg, HER2, MET exon 14, RET, NTRK gene fusions)
  • Correlation between PD-L1 tumor proportion score and responsiveness to anti-PD-1/PD-L1 therapy; implications of the Phase III KEYNOTE-042 trial results
  • Results from the Phase III KEYNOTE-189 trial; patient selection for and current role of carboplatin/pemetrexed/pembrolizumab as first-line therapy for nonsquamous NSCLC
  • Key efficacy and safety findings from the Phase III IMpower150 study evaluating atezolizumab/bevacizumab in combination with carboplatin/paclitaxel for previously untreated advanced nonsquamous NSCLC
  • Emerging role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced squamous NSCLC; results from the Phase III KEYNOTE-407 and IMpower131 trials
  • Biologic rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies; results from the Phase III CheckMate 227 trial evaluating nivolumab/ipilimumab for lung cancer with a high tumor mutational burden
  • Major efficacy and safety findings from the PACIFIC trial; role of sequential durvalumab in the management of unresectable Stage III NSCLC
  • Ongoing evaluation of other anti-PD-1/PD-L1 antibodies in the localized and locally advanced settings
  • Biologic rationale for and available data with immune checkpoint inhibition in small cell lung cancer (SCLC); NCCN endorsement of nivolumab/ipilimumab for patients with progressive metastatic SCLC
  • Design, eligibility criteria and key efficacy outcomes from the Phase III IMpower133 trial of carboplatin/etoposide with or without atezolizumab for patients with untreated extensive-stage SCLC

MODULE 6: Acute Leukemias 2:15 PM – 3:00 PM

  • Assessment, incidence and prognostic or predictive relevance of cytogenetic and other molecular biomarkers (eg, FLT3 mutations, IDH1/2 mutations)
  • Available data with and current clinical role of CPX-351 for newly diagnosed, therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes
  • Current management approaches for FLT3-mutated AML
  • Mechanisms of action, available research and emerging Phase III data with gilteritinib and quizartinib for FLT3 mutation-positive AML
  • Research database supporting FDA approvals of the IDH inhibitors enasidenib and ivosidenib for R/R AML; optimal integration into current algorithms
  • Current clinical role of gemtuzumab ozogamicin for CD33-positive AML
  • Available data and ongoing evaluation of venetoclax in the management of AML
  • Selection and sequencing of therapy for patients with Philadelphia chromosome-positive and negative acute lymphoblastic leukemia (ALL)
  • FDA-endorsed use of blinatumomab for patients with minimal residual disease (MRD)-positive ALL in first or second complete remission or those with R/R disease
  • Research data supporting the FDA endorsement of inotuzumab ozogamicin for R/R B-cell precursor ALL
  • Optimal integration of tisagenlecleucel into the treatment of progressive ALL in pediatric and young adult patients; ongoing clinical investigation of anti-CD19 chimeric antigen receptor (CAR) T-cell platforms in adult populations
  • Current management of acute promyelocytic leukemia

MODULE 7: Genitourinary Cancers 3:10 PM – 4:00 PM

  • Phase III research data, FDA approvals and current clinical roles of apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (CRPC)
  • Mechanism of action, available research data and ongoing Phase III investigation of the novel antiandrogen darolutamide
  • Current management of hormone-sensitive metastatic prostate cancer
  • Clinical and biologic factors guiding the selection and sequencing of secondary hormonal therapy, immunotherapy and cytotoxic therapy for metastatic CRPC (mCRPC)
  • Published research documenting the correlation between the presence of AR-V7 (androgen receptor splice variant 7) and outcomes with secondary hormonal therapy or chemotherapy for patients with mCRPC
  • Current indications for radium-223 dichloride in clinical practice and rational combination strategies
  • Incidence of somatic or germline mutations (eg, BRCA1, BRCA2 or ATM) in patients with mCRPC; ongoing evaluation of PARP inhibition as a therapeutic strategy
  • Selection and sequencing of therapy for patients with metastatic renal cell carcinoma (mRCC)
  • Available data with anti-PD-1 monotherapy as front-line treatment for mRCC; implications for future trial design and clinical practice
  • Key clinical findings from the IMmotion151 study of atezolizumab/bevacizumab versus sunitinib for untreated mRCC
  • FDA breakthrough therapy designations and ongoing evaluation of avelumab/axitinib and pembrolizumab/lenvatinib for mRCC
  • Research database supporting the FDA approvals of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab for urothelial bladder cancer (UBC); patient selection and use of these agents in clinical practice
  • Rationale for and clinical implications of recent revision of FDA approvals of atezolizumab and pembrolizumab limiting their use for patients with metastatic UBC who have not received prior therapy
  • FDA breakthrough therapy designation for enfortumab vedotin for patients with locally advanced or metastatic UBC who previously received immune checkpoint inhibitor therapy; ongoing trials and development timeline

CE Information

Target Audience:
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

Accreditation Statements:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CME Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit Designation Statements:
This educational activity for 6.6 contact hours is provided by Research To Practice.

This activity is awarded 6.6 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit ResearchToPractice.com/Meetings/YIR2018/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

CME Credit Form:
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Form:
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Educational Support:
This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech, Genomic Health Inc, Guardant Health, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, Taiho Oncology Inc and Tesaro Inc.

Research To Practice CME/CNE Planning Committee Members, Staff and Reviewers:
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Location

Fairmont Miramar Hotel & Bungalows
101 Wilshire Blvd
Santa Monica, CA 90401
Hotel phone: (310) 576-7777

Meeting Room: Starlight Ballroom (Lobby Level)

Room Reservations:

At this time, the Year in Review group housing block is full. To secure accommodations, please contact the Fairmont Miramar Hotel & Bungalows hotel directly at (310) 576-7777. The hotel will offer their best available rate based on availability.

For driving and public transportation directions to Fairmont Miramar Hotel & Bungalows, please visit the resort website.

Registration

Thank you for your interest in our Year in Review program. At this time online preregistration is closed for this event. However, seats are still available for the program. Onsite registration will be open starting at 7:00 AM on Saturday, November 17th. If you are interested in attending, please visit our registration desk located in the Starlight Ballroom foyer on the Lobby Level of the Fairmont Miramar Hotel & Bungalows hotel (101 Wilshire Boulevard, Santa Monica, CA 90401).

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.